Quantcast
Last updated on April 19, 2014 at 7:22 EDT

Latest G protein Stories

2012-11-15 08:30:12

SEATTLE, Nov. 15, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that GPR17-targeting compounds, which were previously identified by Omeros in connection with unlocking this orphan receptor, have now been demonstrated to promote differentiation of the cells that form myelin in the central nervous system. Myelin is critical for the proper functioning of the nervous system, and demyelination is associated with multiple nervous system disorders, including multiple...

2012-10-24 07:30:31

SEATTLE, Oct. 24, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors (GPCRs). Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 46 Class A orphan GPCRs, representing almost 60 percent of these targets and equaling the number of GPCRs that are...

2012-10-18 07:25:04

WELWYN GARDEN CITY, England and BOSTON, October 18, 2012 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau, will represent the Company at the 2nd Annual Global Discovery to Development Innovation Summit (GDDIS 2012 [http://www.gddis.com ]) which takes place at The Westin, Philadelphia, PA, USA (22-23 October 2012). Mr Grau will also participate on a panel discussion on Rare Diseases at the Boston Biotech...

Nobel Prize In Chemistry Awarded To Two US Scientists
2012-10-10 13:55:53

redOrbit Staff & Wire Reports - Your Universe Online Groundbreaking research into how the protein receptors of cells detect and respond to external signals -- work that could lead to the development of better drugs to combat cancer and diabetes -- has earned two US scientists the 2012 Nobel Prize in Chemistry. Sixty-nine year old Robert Lefkowitz, a professor at Duke University Medical Center, and 57-year-old Brian Kobilka, a professor at Stanford University School of Medicine, were...

2012-09-12 10:25:17

WELWYN GARDEN CITY, England and BOSTON, September 12, 2012 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau, will represent the Company at the 5th CNS Partnering and Deal-making conference [http://www.gtcbio.com/component/conference/?file=home&cn=5th+CNS+Partnering+and+Deal-making&cid=38 ] , which takes place at the Hilton San Francisco Financial District, San Francisco, CA (13-14 September)....

2012-06-21 21:01:16

Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites. Researchers from Cincinnati Children's Hospital Medical Center report their findings online June 21 in Chemistry & Biology. The scientists named their lead drug candidate "Rhosin" and hope future testing shows it to be promising for the treatment of various cancers or nervous system...

2012-06-21 06:24:10

CINCINNATI, June 21, 2012 /PRNewswire-USNewswire/ -- Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Researchers from Cincinnati Children's Hospital Medical Center report their findings online June 21 in Chemistry & Biology. The scientists named their lead drug...

2012-06-12 06:23:43

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified several proteins that help regulate cells´ response to light–and the development of night blindness, a rare disease that abolishes the ability to see in dim light. In the new studies, published recently in the journals Proceedings of the National Academy of Sciences (PNAS) and The Journal of Cell Biology, Scripps Florida scientists were able to show that a family of...

2012-05-03 02:31:34

SEATTLE, May 3, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors (GPCRs). Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 37 of them, representing over 45 percent of the Class A orphan GPCRs. There are approximately 120 orphan GPCRs and Omeros...

2012-02-29 06:00:00

SEATTLE, Feb. 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of the following six orphan G protein-coupled receptors (GPCRs): GPR17, GPR153, CCRL2, LGR4, LGR6 and OPN5. Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 33 of them, representing over 40 percent of the Class A orphan...